TG Therapeutics Inc (NASDAQ: TGTX) has seen a rise in its stock price by 6.21 in relation to its previous close of 12.07. However, the company has experienced a 25.07% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-06 that The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?

Additionally, the 36-month beta value for TGTX is 2.23. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price predicted by analysts for TGTX is $27.81, which is $14.99 above the current price. The public float for TGTX is 137.37M and currently, short sellers hold a 26.95% ratio of that float. The average trading volume of TGTX on November 21, 2023 was 5.31M shares.

TGTX’s Market Performance

TGTX stock saw an increase of 25.07% in the past week, with a monthly gain of 89.93% and a quarterly increase of 21.52%. The volatility ratio for the week is 7.43%, and the volatility levels for the last 30 days are 8.77% for TG Therapeutics Inc (TGTX). The simple moving average for the past 20 days is 34.93% for TGTX’s stock, with a -25.24% simple moving average for the past 200 days.

Analysts’ Opinion of TGTX

Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the current year 2023.

TGTX Trading at 45.27% from the 50-Day Moving Average

After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.06% of loss for the given period.

Volatility was left at 8.77%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares surge +91.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.72% upper at present.

During the last 5 trading sessions, TGTX rose by +25.07%, which changed the moving average for the period of 200-days by -26.15% in comparison to the 20-day moving average, which settled at $9.81. In addition, TG Therapeutics Inc saw 8.37% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TGTX starting from WEISS MICHAEL S, who purchase 100,000 shares at the price of $10.13 back on Aug 11. After this action, WEISS MICHAEL S now owns 12,073,021 shares of TG Therapeutics Inc, valued at $1,013,000 using the latest closing price.

Lonial Sagar, the Director of TG Therapeutics Inc, sale 34,854 shares at $23.37 during a trade that took place back on Jun 23, which means that Lonial Sagar is holding 93,878 shares at $814,538 based on the most recent closing price.

Stock Fundamentals for TGTX

Current profitability levels for the company are sitting at:

The net margin for TG Therapeutics Inc stands at -7121.54. The total capital return value is set at -84.24, while invested capital returns managed to touch -87.40. Equity return is now at value -19.53, with -9.44 for asset returns.

Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 141.77 points at debt to equity in total, while total debt to capital is 58.64. Total debt to assets is 42.91, with long-term debt to equity ratio resting at 139.07. Finally, the long-term debt to capital ratio is 57.52.

When we switch over and look at the enterprise to sales, we see a ratio of 9.22, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 4.01 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.16.


In conclusion, TG Therapeutics Inc (TGTX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.